NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market on Tuesday that its second quarter revenues rose 16 percent from Q2 2015, thanks in large part to a 12 percent increase in the number of Oncotype Dx tests delivered during the quarter.

For the three months ended June 30, the firm reported total revenues of $82.0 million, up from $70.6 million a year ago, and beating the consensus Wall Street estimate of $81.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.